1. Home
  2. WLK vs NUVL Comparison

WLK vs NUVL Comparison

Compare WLK & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westlake Corporation

WLK

Westlake Corporation

HOLD

Current Price

$111.53

Market Cap

12.8B

Sector

Industrials

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$98.09

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLK
NUVL
Founded
1986
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8B
8.1B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
WLK
NUVL
Price
$111.53
$98.09
Analyst Decision
Buy
Strong Buy
Analyst Count
15
15
Target Price
$98.73
$135.33
AVG Volume (30 Days)
1.2M
436.1K
Earning Date
05-26-2026
05-27-2026
Dividend Yield
1.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,170,000,000.00
N/A
Revenue This Year
$3.18
N/A
Revenue Next Year
$4.41
$1,064.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$56.33
$55.54
52 Week High
$114.65
$113.02

Technical Indicators

Market Signals
Indicator
WLK
NUVL
Relative Strength Index (RSI) 64.38 42.01
Support Level $73.33 $73.22
Resistance Level N/A $107.13
Average True Range (ATR) 5.83 3.82
MACD 0.30 -0.35
Stochastic Oscillator 74.72 19.08

Price Performance

Historical Comparison
WLK
NUVL

About WLK Westlake Corporation

Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: